Techcyte has partnered with Modella AI to integrate its AI-powered digital diagnostic platform, Techcyte Fusion, with Modella AI’s advanced PathChat tool.
The collaboration aims to improve research-use pathology workflows by incorporating advanced AI capabilities.
The integration will enhance operational efficiency through intelligent slide interactions and report summarisation.
Modella AI’s PathChat, which received a breakthrough device designation from the US Food and Drug Administration (FDA), facilitates enhanced digital slide analysis.
PathChat will be used within the Techcyte Fusion platform, strictly for research purposes, excluding clinical diagnostic applications.
Modella AI president, cofounder, and CEO Jill Stefanelli said: “We’re excited to partner with Techcyte to bring our pathology-native AI to a broader research audience.
“Integrating PathChat into the Fusion research platform supports the exploration of AI-assisted workflows in pathology and reflects our shared commitment to advancing digital innovation in the lab.”
Based in Boston, Modella AI is focused on generative and agentic AI to transform medical workflows and improve patient care.
Techcyte’s AI-powered digital diagnostics platform combines anatomic and clinical pathology processes.
The integration of Modella AI’s technology into Techcyte Fusion represents a crucial step in advancing digital pathology research.
By addressing increasing workload demands and case complexities, the collaboration seeks to enhance the capabilities of pathologists.
The partnership provides a unified system that supports improved diagnostic accuracy and interoperability.
Techcyte chief strategy officer Matt Smith said: “Modella AI’s commitment to innovation, including agentic AI, and Techcyte’s unified pathology platform create a powerful research combination.
“Together, our goal is delivering practical AI that pathologists can trust and that seamlessly integrates into their digital workflows.”
